{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=8",
    "query": {
      "intervention": "Vehicle solution",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 454,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T20:49:46.764Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06349759",
      "title": "Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mesopic Vision",
        "Night Vision Loss"
      ],
      "interventions": [
        {
          "name": "phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opus Genetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2024-04-01",
      "completion_date": "2026-02-19",
      "has_results": true,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-19T20:49:46.764Z",
      "location_count": 25,
      "location_summary": "Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more",
      "locations": [
        {
          "city": "Pheonix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06349759"
    },
    {
      "nct_id": "NCT01257191",
      "title": "A Study to Compare the Effects of Different Sized Particles on Cells in the Nose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypersensitivity, Immediate",
        "Atopic Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "Carbon Black",
          "type": "DRUG"
        },
        {
          "name": "Diesel Exhaust Particles",
          "type": "DRUG"
        },
        {
          "name": "Fine Concentrated Ambient Particles",
          "type": "DRUG"
        },
        {
          "name": "Ultrafine Concentrated Ambient Particles",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2010-04",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-10-19T20:49:46.764Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257191"
    },
    {
      "nct_id": "NCT02128113",
      "title": "RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Corneal Endothelial Cell Loss",
        "Ocular Pain",
        "Ocular Inflammation",
        "Cataract Surgery"
      ],
      "interventions": [
        {
          "name": "Vehicle Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Ophthalmic Suspension 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Ophthalmic Suspension 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 307,
      "start_date": "2014-05-31",
      "completion_date": "2015-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-10-19T20:49:46.764Z",
      "location_count": 15,
      "location_summary": "Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Cape Coral",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Hoffman Estates",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02128113"
    },
    {
      "nct_id": "NCT04324359",
      "title": "Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-surgical Ocular Inflammation",
        "Post-surgical Ocular Pain"
      ],
      "interventions": [
        {
          "name": "SURF-201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Surface Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2020-03-03",
      "completion_date": "2020-11-20",
      "has_results": true,
      "last_update_posted_date": "2025-01-15",
      "last_synced_at": "2026-10-19T20:49:46.764Z",
      "location_count": 10,
      "location_summary": "Hemet, California • Murrieta, California • Brooksville, Florida + 7 more",
      "locations": [
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Stuart",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04324359"
    },
    {
      "nct_id": "NCT01787448",
      "title": "RIPT of Ibuprofen Topical Gel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Topical gel vehicle",
          "type": "DRUG"
        },
        {
          "name": "Sodium lauryl sulfate 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Sodium chloride solution 0.9% (saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2013-01",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-10-19T20:49:46.764Z",
      "location_count": 1,
      "location_summary": "Carlstadt, New Jersey",
      "locations": [
        {
          "city": "Carlstadt",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01787448"
    },
    {
      "nct_id": "NCT02780115",
      "title": "A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "AGN-199201 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AGN-190584 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Vehicle",
          "type": "DRUG"
        },
        {
          "name": "AGN-190584 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "40 Years to 55 Years"
      },
      "enrollment_count": 151,
      "start_date": "2016-05-26",
      "completion_date": "2017-10-31",
      "has_results": true,
      "last_update_posted_date": "2020-12-22",
      "last_synced_at": "2026-10-19T20:49:46.764Z",
      "location_count": 25,
      "location_summary": "Arcadia, California • Artesia, California • Cypress, California + 19 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02780115"
    },
    {
      "nct_id": "NCT06413095",
      "title": "PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MK-0482 + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MK-4830 + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Presage Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2022-06-01",
      "completion_date": "2023-06-22",
      "has_results": false,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-10-19T20:49:46.764Z",
      "location_count": 11,
      "location_summary": "Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06413095"
    },
    {
      "nct_id": "NCT02807428",
      "title": "Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-surgical Pain"
      ],
      "interventions": [
        {
          "name": "AYX1 Injection 660 mg/6 mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection 6 mL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adynxx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2017-02-20",
      "completion_date": "2017-12-19",
      "has_results": false,
      "last_update_posted_date": "2018-10-17",
      "last_synced_at": "2026-10-19T20:49:46.764Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807428"
    },
    {
      "nct_id": "NCT03278028",
      "title": "A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Common Wart"
      ],
      "interventions": [
        {
          "name": "A-101 Topical Solution",
          "type": "DRUG"
        },
        {
          "name": "A-101 Vehicle Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2017-07-13",
      "completion_date": "2018-03-01",
      "has_results": true,
      "last_update_posted_date": "2019-04-09",
      "last_synced_at": "2026-10-19T20:49:46.764Z",
      "location_count": 16,
      "location_summary": "Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 13 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03278028"
    },
    {
      "nct_id": "NCT03207906",
      "title": "A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chemotherapy-Associated Paronychia"
      ],
      "interventions": [
        {
          "name": "VBP-926",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloce BioPharma LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2017-10-24",
      "completion_date": "2018-09-18",
      "has_results": false,
      "last_update_posted_date": "2019-01-25",
      "last_synced_at": "2026-10-19T20:49:46.764Z",
      "location_count": 8,
      "location_summary": "Fountain Valley, California • Chicago, Illinois • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207906"
    }
  ]
}